Moderna surges 33.5% after the company outlines plans to expand its mRNA platform beyond vaccines into oncology, autoimmune diseases and cell therapies.
When a stock and the analysts covering it disagree this sharply, one of them is about to be wrong.
Morning Overview on MSN
An mRNA vaccine halved the odds of aggressive melanoma returning after surgery
People treated for aggressive melanoma now have a concrete reason to watch a single experimental combination closely. In a ...
Moderna expands beyond vaccines while Recursion bets on AI-driven drug discovery, each with distinct risks, partnerships, and ...
The "Mad Money" host revisits a stock he spent years dismissing.
Since 2020, average wealth per US adult has grown 10%, while median wealth has fallen 20%.
From space to healthcare and artificial intelligence, what could the next 250 years of the United States look like?
University of Medicine and Health Sciences has shown success in targeting neuroblastoma. The research represents an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results